

Evento ALDAI: «Prevenzione cardiovascolare»

Milano, 16 ottobre 2018

La prevenzione in ambito cardiovascolare oltre
le linee guida: *dove siamo, cosa ci attende?*

Riccardo Bigi MD, PhD, EFESC
Centro Diagnostico Italiano, Milano







Le cose migliori della vita o sono illegali
o sono immorali o fanno ingrassare.


O. Wilde



Basi razionali della prevenzione CV

- 1. Le malattie CV rappresentano la causa primaria di mortalità, morbidità e disabilità nei paesi avanzati**

Mortalità per malattie CV negli USA



Mozaffarian D et al. Circulation. 2015;131:e29-e322




Mortalità per malattie CV

- Circa 735.000 americani subiscono un attacco cardiaco ogni anno. Per 525,000 di loro si tratta del primo episodio, mentre per 210,000 di una recidiva.
- Il 20% della popolazione americana è affetta da una patologia CV.
- In Europa, le malattie CV causano ogni anno oltre 4 milioni di decessi di cui circa 2 milioni nella sola UE.
- La patologia CV è causa del 47% della mortalità globale in Europa e del 40% di quella in UE.




Confronto fra mortalità CV e per cancro in rapporto all'età



Mozaffarian D et al. Circulation. 2015;131:e29-e322



Andamento della mortalità CV per sesso negli USA




Mozaffarian D et al. Circulation. 2015;131:e29-e322




Cause di mortalità in Europa

Deaths by cause, men, latest available year, Europe




Deaths by cause, women, latest available year, Europe




Basi razionali della prevenzione CV

- 2. Le malattie CV rappresentano una fonte primaria di costi diretti ed indiretti per i sistemi sanitari**


Costi economici della patologia CV




Costi diretti dell'assistenza sanitaria negli USA (miliardi di \$)




Ripartizione degli indici di spesa per malattie CV in EU




Proiezioni dei costi per malattie CV negli USA (miliardi di \$)



Proiezioni dei costi per malattie CV negli USA (miliardi di \$)



Principali fattori di incremento dei costi



Source: Smith, Heffler and Freeland, 2000



CLINICAL PERSPECTIVE

Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age

Donald M. *Circulation*. 2006;113:791-798

- Despite 4 decades of declining mortality, CVD remains by far the leading cause of morbidity and mortality in developed countries and it is soon to be the leading cause of morbidity and mortality in the developing world
- Recent data suggest disturbing increases in the prevalence of CVD risk factors such as diabetes, obesity, and the metabolic syndrome which may reverse downward trends in CVD mortality
- In the face of the enormous public health burden imposed by CVD, renewed **efforts are needed to promote prevention**



Basi razionali della prevenzione CV

3. Le malattie CV possono essere un killer silente

Il killer silente


- Il rischio di sviluppare nel corso della vita una patologia CV sintomatica nei 50enni arruolati nel Framingham Heart Study era pari al 52% fra gli uomini e al 39% fra le donne
- Nel 30% - 50% dei casi, la patologia esordiva con un evento catastrofico, come ictus, infarto miocardico o morte improvvisa




Basi razionali della prevenzione CV

4. Le malattie CV hanno carattere progressivo

Evoluzione della patologia aterosclerotica



Sviluppo progressivo di malattia CV




Strategia di lotta ai fattori di rischio

Moriyama IM et al. J Chronic Dis. 1958;7:401-412

Observation on possible factors responsible for the sex and race trends in cardiovascular-renal mortality in the United States





Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Salim Yusuf, Steven Hawken, Stephanie Öunpuu, Tony Dans, Alvaro Avezum, Fernando Lanas, Matthew McQueen, Andrzej Budaj, Prem Pais, John Varigos, Liu Lisheng, on behalf of the INTERHEART Study Investigators*

Summary

Background Although more than 80% of the global burden of cardiovascular disease occurs in low-income and middle-income countries, knowledge of the importance of risk factors is largely derived from developed countries. Therefore, the effect of such factors on risk of coronary heart disease in most regions of the world is unknown.

Methods We established a standardised case-control study of acute myocardial infarction in 52 countries, representing every inhabited continent. 15 152 cases and 14 820 controls were enrolled. The relation of smoking, history of hypertension or diabetes, waist/hip ratio, dietary patterns, physical activity, consumption of alcohol, blood apolipoproteins (Apo), and psychosocial factors to myocardial infarction are reported here. Odds ratios and their 99% CIs for the association of risk factors to myocardial infarction and their population attributable risks (PAR) were calculated.

Findings Smoking (odds ratio 2·87 for current vs never, PAR 35·7% for current and former vs never), raised ApoB/ApoA1 ratio (3·25 for top vs lowest quintile, PAR 49·2% for top four quintiles vs lowest quintile), history of hypertension (1·91, PAR 17·9%), diabetes (2·37, PAR 9·9%), abdominal obesity (1·12 for top vs lowest tertile and 1·62 for middle vs lowest tertile, PAR 20·1% for top two tertiles vs lowest tertile), psychosocial factors (2·67, PAR 32·5%), daily consumption of fruits and vegetables (0·70, PAR 13·7% for lack of daily consumption), regular alcohol consumption (0·91, PAR 6·7%), and regular physical activity (0·86, PAR 12·2%), were all significantly related to acute myocardial infarction ($p < 0·0001$ for all risk factors and $p = 0·03$ for alcohol). These associations were noted in men and women, old and young, and in all regions of the world. Collectively, these nine risk factors accounted for 90% of the PAR in men and 94% in women.

Interpretation Abnormal lipids, smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, consumption of fruits, vegetables, and alcohol, and regular physical activity account for most of the risk of myocardial infarction worldwide in both sexes and at all ages in all regions. This finding suggests that approaches to prevention can be based on similar principles worldwide and have the potential to prevent most premature cases of myocardial infarction.



Lancet 2004; 364: 937–52

Published online
September 3, 2004
<http://image.thelancet.com/extras/04art8001web.pdf>

See [Comment](#) page 912


*Listed at end of report.

Population Health Research
Institute, Hamilton General
Hospital, 237 Barton Street
East, Hamilton, Ontario,
Canada L8L 2X2
(Prof S Yusuf DPhil,
S Öunpuu PhD, S Hawken MSc,
T Dans MD, A Avezum MD,
F Lanas MD, M McQueen FRCP,
A Budaj MD, P Pais MD,
J Varigos BSc, L Lisheng MD)

Correspondence to:
Prof Salim Yusuf
yusufs@mcmaster.ca



INTERHEART: Association of risk factors with acute MI




Adjusted for age, sex, geographic region
Note: odds ratio plotted on a doubling scale


Yusuf S et al. *Lancet*. 2004;364:937-52.



Relazione fra fattori di rischio e mortalità standardizzata per età



% di decessi per malattie CV attribuibile ai singoli fattori di rischio



Wilkins E, et Al. (2017). European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels.




Indicatori ideali di salute (ARIC) 1987-2006

- never smoking or quitting >12 months ago;
- BMI <25 kg/ m²;
- 4–5 components of a healthy diet score;
- ≥75 minutes/week of vigorous physical activity [or 150 minutes/week of moderate or moderate + vigorous activity]
- untreated total cholesterol <200 mg/dL,
- untreated blood pressure <120 mmHg systolic and 80 mmHg diastolic
- untreated fasting serum glucose <100 mg/dL




Curve di sopravvivenza per incidenza di cancro in rapporto agli indicatori di salute (ARIC) 1987-2006



*Bisogna cercare di rendere le cose il più semplici possibile,
ma non più semplici di quel che sia possibile*

Albert Einstein








Kostis WJ, Circ Cardiovasc Qual Outcomes 2010; 3:581-589



Trends in age-specific CHD mortality rates in US, 1979 to 2011



Fattori di rischio e Suscettibilità

Sir Winston Churchill, 91 †




Jim Fixx, 53 †♥



Limiti del ruolo del LDL colesterolo nella cardiopatia ischemica

Framingham Heart Study - 26 anni di FU

- Esiste un significativo overlap fra i livelli di LDL colesterolo fra le popolazioni con e senza C.I.
- L' 80% of dei pazienti con IM presentavano valori di LDL colesterolo simili a quelli dei soggetti senza IM



Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force

Mark Helfand, MD, MPH; David I. Buckley, MD, MPH; Michele Freeman, MPH; Rongwei Fu, PhD; Kevin Rogers, MD; Craig Fleming, MD; and Linda L. Humphrey, MD, MPH

Ankle-brachial index
C-reactive protein
Carotid intima media thickness
Electron beam computed tomography
Fasting glucose
Homocysteine
Lipoprotein(a)
Periodontal disease
White blood cell count

Conclusion: The current evidence does not support the routine use of any of the 9 risk factors for further risk stratification of intermediate-risk persons.




Potenziati fattori di rischio addizionali

Angiotensin-converting enzyme genotype,
ApoE genotype
Apolipoproteins A1 and B
Cystatin C
D-dimer
Electrocardiogram findings
Exercise treadmill testing
Factors V, VII, and VIII
Fibrinogen
Fibrinopeptide A
Heart rate
High-density lipoprotein subtypes
Infectious agents: Cytomegalovirus, Chlamydia pneumonia, Helicobacter pylori, Herpes viruses
Insulin resistance
Interleukins (e.g., IL-6)
Lipoprotein-associated phospholipase A(2)
Metabolic syndrome
Microalbuminuria
Oxidized LDL
PAI-1 genotype
Physical inactivity
Plasminogen activator inhibitor 1 (PAI-1)
Platelet activity
Platelet aggregation
Platelet size and volume
Prothrombin fragment 1 + 2
Pulse pressure
Remnant lipoproteins
Serum amyloid A
Soluble CD40 ligand
Tissue-plasminogen activator
Vascular and cellular adhesion molecules
von Willebrand factor antigen
Waist-to-hip ratio



Coronary stenosis severity prior to MI




Falk E, et al. *Circulation*. 1995;92:657-671




Anatomic approach: limitations


Diameter >100 micron




Diameter 20-350 micron




Prognostic and clinical correlates of angiographically diffuse non-obstructive coronary lesions



Eterogeneità e complessità dell'origine della patologia CV



Trends dei tassi di mortalità fra 25-64 anni in Russia, 1980-2010




Aspetti critici attuali della prevenzione e cura delle malattie CV

- ☐ Necessità di riduzione dei costi
- ☐ Insufficiente rapporto costo/efficacia
- ☐ Eccesso di utilizzo di risorse
- ☐ Elevati tassi di re-ospedalizzazione e mortalità



Prospective future



FUTURE OF CARDIOLOGY

INVASIVE

PREVENTIVE

3D PRINTING



GENOMICS

EMR



NANOTECHNOLOGY



TISSUE ENGINEERING



ARTIFICIAL INTELLIGENCE



SENSORS



VARIABILITA' GENETICA

Il genoma umano è costituito da circa 3 miliardi di coppie di basi di DNA alloggiate in 23 coppie di cromosomi che formano da 20.000 a 25.000 geni



	Framingham	SCORE	ASSIGN	QRISK	PROCAM
Popolazione (tipo)	generale (Framingham)	12 studi in paesi europei	generale (Scozia)	database dei medici di MG	impiegati
Selezione	volontari	casuale + coorti occupazionali	casuale	consecutiva	volontari
Evento previsto (outcome)	ogni evento CV a 10 anni	mortalità CV a 10 anni	ogni evento CV a 10 anni	ogni evento CV a 10 anni	2 scores separati per ogni evento CV e per soli eventi cerebrovascolari a 10 anni
Età	30-75	40-65	30-74	20-75	40-79
Variabili incluse	sesso, età, colesterolo, HDL, PA, fumo, diabete, terapia antipertensiva	sesso, età, colesterolo totale o rapporto tot/HDL, PA, fumo	sesso, età, colesterolo tot, HDL, PA, fumo, diabete, deprivazione sociale, familiarità	sesso, età, colesterolo tot/HDL, PA, fumo, diabete, deprivazione sociale, terapia antipertensiva, familiarità, BMI, etnicità, FA, malattie croniche	età, sesso, LDL, HDL, diabete, fumo, ipertensione
Formato	in origine fogli per calcolo, in seguito carte a colori, calcolatore online o portatile	carte a colori, versione elettronica	calcolatore online	calcolatore online, software dedicato	fogli di calcolo, calcolatore online
Raccomandazione in linee guida	National Cholesterol Education Program (USA)	Linee guida europee per la prevenzione CV	Scottish Intercollegiate Guidelines Network	National Institute for Health and Clinical Excellence (UK)	International Task Force for Prevention of Coronary Disease
Sito Web	www.nhlbi.nih.gov/guidelines/cholesterol/index/htm	www.HeartScore.org	www.assign-score.com	www.qrisk.co.uk	www.chd-taskforce.com/calculator





AMERICAN
COLLEGE *of*
CARDIOLOGY

Personalized Medicine: Definition


“Personalized medicine is the use of diagnostic and screening methods to better manage the individual patient’s disease or predisposition toward a disease....

“Personalized medicine will enable risk assessment, diagnosis, prevention, and therapy specifically tailored to the unique characteristics of the individual, thus enhancing the quality of life and public health.”

– NHLBI Strategic Planning, Theme #10



The Challenge





AMERICAN
COLLEGE *of*
CARDIOLOGY



Concept of “Biosignature”

Cardiovascular Insult or Therapy

Patient A

Patient B

Gene chips



“Biosignatures”

Outcome A

Outcome B

Personalized, Predictive, Prevention

Decision
Support Tools:

Assess Risk

Refine Assessment

Predict/Diagnose

Monitor Progression
Predict Events
Inform Therapeutics



Sources of
New
Biomarkers:

Baseline Risk


- Stable Genomics
- SNPs
- Haplotype Mapping
- Gene Sequencing


Preclinical
Progression

- Dynamic Testing
- Gene Expression
- Proteomics
- Metabolomics
- Clinical Risk Models

Disease Initiation and Progression


- Clinical Decision Support
- Risk Models
- Theranostics





Krittanawong, C. et al. J Am Coll Cardiol. 2017;69(21):2657-64.







“If it were not for the great
variability among individuals,
medicine might as well be a
science and not an **art**”

Sir William Osler, 1892